A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to day and night closed-loop control using the DreaMed Substance Administration Device Software in Adolescent and Adult Subjects with Type 1 Diabetes mellitus.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 22 Mar 2018 Status changed from recruiting to completed.
- 20 Feb 2017 New trial record